All news

Oragenics reports millions in losses and going concern doubt

Alpha Vantage · Quantisnow · · AI-summarised by FinFlash

Oragenics reported a $7.3 million nine-month net loss and used $6.4 million in operating cash, raising substantial doubt regarding its ability to continue as a going concern. The company warned that research and development programs face delays or abandonment without new financing. For investors, unresolved liquidity risks threaten ongoing clinical operations and potential solvency.

Read original source

OGEN company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.